Strides Pharma UK choose Mawdsleys as their distributor to hospitals
Strides Pharma UK choose Mawdsleys as their distributor to hospitals 20th September 2017

Mawdsleys will be distributing Strides Pharma UK products to English hospitals as part of CMU contract

 

Mawdsleys are delighted to be assisting Strides Pharma UK Ltd in distributing the following products to English hospitals for CMU contract CM/PHG/15/5467/01:

 

Description: Prednisolone Tabs 5mg

Pack: 28

PIP Code: 1106046

EAN Code: 005060057401422

Description: Azathioprine Tabs 50mg

Pack: 56

PIP Code: 1173079

EAN Code: 005031676000181

 

These products are listed online and available to order now (September 2017).

 

With Mawdsleys you will benefit from:

·         Industry-leading 22 days average stock holding

·         EDI or online ordering

·         Live stock levels, prices and invoices, as well as managing back orders, online

·         No minimum order levels

·         Reliable and accurate daily deliveries from your local depot

·         Working together to make efficiency savings

 

Stock is available now (September 2017). Order from Mawdsleys through your normal preferred route i.e. EDI, through the Mawdsleys online ordering system, Mawdsleys Online, or by calling or faxing Customer Services.

 

Should you have any queries, please contact your Mawdsleys Regional Hospital Account Manager. You may also contact Mawdsleys customer service on 0844 736 9016 or email info@mawdsleys.co.uk

 

Other latest news
https://www.mawdsleys.co.uk/news/keeping-medicines-moving-during-contract-change-and-beyond/ thumbnail image Keeping medicines moving during contract change and beyond

We recently sent the last of the Wave 14 contract packs to our hospital customers ready for the contract changeover on 1st June.   They contained all the essentials to help them with the contract change including the all-important, fully checked, Mawdsleys product list complete with EAN, PIP and NPC…

Read more
https://www.mawdsleys.co.uk/news/mawdsleys-and-oncoscience-launch-a-named-patient-program-for-cimaher-nimotuzumab-in-the-uk-and-ireland/ thumbnail image Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher®

Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.   Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of…

Read more
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.